Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.60B P/E - EPS this Y -6.60% Ern Qtrly Grth -
Income -176.06M Forward P/E -11.86 EPS next Y -60.70% 50D Avg Chg 4.00%
Sales 243.23M PEG -2.45 EPS past 5Y - 200D Avg Chg -12.00%
Dividend N/A Price/Book 9.02 EPS next 5Y 7.33% 52W High Chg -55.00%
Recommedations 2.00 Quick Ratio 2.72 Shares Outstanding 106.01M 52W Low Chg 27.00%
Insider Own 2.56% ROA -15.91% Shares Float 103.26M Beta 1.41
Inst Own 68.31% ROE -42.68% Shares Shorted/Prior 3.73M/3.94M Price 33.93
Gross Margin 100.00% Profit Margin -72.39% Avg. Volume 868,235 Target Price 71.23
Oper. Margin -73.39% Earnings Date Jan 31 Volume 863,113 Change 5.97%
Arrowhead Pharmaceuticals, Inc. News
11/30/22 ARWR: Sells Olpasiran Royalty Interest for $250 Million…
11/29/22 Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
11/28/22 Edited Transcript of ARWR.OQ earnings conference call or presentation 28-Nov-22 9:30pm GMT
11/28/22 Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
11/23/22 We Think Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Easily Afford To Drive Business Growth
11/21/22 Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
11/14/22 Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
11/09/22 Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
11/09/22 Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
11/07/22 Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
10/13/22 Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
10/11/22 Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
10/09/22 Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) recent 4.3% pullback adds to one-year year losses, institutional owners may take drastic measures
09/07/22 Investing in Arrowhead Pharmaceuticals (NASDAQ:ARWR) five years ago would have delivered you a 982% gain
09/01/22 Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
08/17/22 Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
08/09/22 ARWR: Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates…
11:00 PM Arrowhead Pharmaceuticals (ARWR) Q3 2022 Earnings Call Transcript
03:00 PM Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

ARWR Chatroom

User Image tickeron Posted - 15 hours ago

$ALNY vs. $ARWR: which stock is the best to buy? #AlnylamPharmaceuticals https://srnk.us/go/4202468

User Image inquisitive1 Posted - 1 day ago

$ARWR Mattie2, by what date?

User Image Mattie2 Posted - 1 day ago

$ARWR I wanna see $100.00 minimum!! I’m over $100k in the hole on this one!

User Image inquisitive1 Posted - 1 day ago

$ARWR Hopefully, next week we can surpass the $35 wall.

User Image Blackouts Posted - 1 day ago

$ARWR trying to breakout $XBI

User Image Blackouts Posted - 1 day ago

$ARWR beautiful

User Image johnnygogogo Posted - 1 day ago

$ARWR if ARWR Discord were an institution, it would be a 13G filer and top 10 (if not a a top 5) owner. Think about that over the weekend and how we should be more coordinated w/ communication to management, list of requests (ie. demands… not that they have any proclivity to adhere to votes). Not trolling… or joking. Really think about it and send me your thoughts. PMs are open.

User Image burstingclownbubbles Posted - 1 day ago

$ARWR despite traders taking profits it's blowing through the bids

User Image inquisitive1 Posted - 1 day ago

$ARWR Hi, nice movement today. When and what is the next likely positive catalyst for the stock?

User Image EarningsInsider Posted - 1 day ago

B. Riley Sets Arrowhead Pharmaceuticals Q1 2023 Earnings Estimates at $1.34 EPS. https://www.marketbeat.com/x/1319811 $ARWR

User Image burstingclownbubbles Posted - 2 days ago

$ARWR I wonder if the real delay for AAT announcement is because the mistletoe is running late. Heard there is a shortage

User Image Pantherfan7979 Posted - 2 days ago

$ARWR Alright for all you negative ARWR folks.....Up 3% and the XBI is flat. Low volume, but it seems selling pressure has subsided. Yes, I know we are only back to $33 but you have to start somewhere. Onwards and upwards.

User Image EarningsInsider Posted - 2 days ago

B. Riley Sets Arrowhead Pharmaceuticals Q2 2023 Earnings Estimates at ($0.90) EPS. https://www.marketbeat.com/x/1319320 $ARWR

User Image stockilluminati Posted - 2 days ago

$ARWR https://www.stockilluminati.com/arwr/news.php - My 24-Stock $353K Portfolio Suffers A Crypto Winter Burn In November

User Image valedavg7f Posted - 2 days ago

$PDD $ARWR $KALA $AAPL Analyst price target for today. 🚀🚀 pre-markets-updates.is-best.net

User Image STCKPRO Posted - 11/30/22

$ARWR NEW ARTICLE : Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Fusion Pharmaceuticals (FUSN) https://www.stck.pro/news/ARWR/38378714

User Image Steve_382 Posted - 11/30/22

$RGLS Well, the other 3 biotech stocks that I follow closely were each up over 7% today. $ALNY $ARWR $VYGR all had nice moves. But, poor $RGLS closed flat. Oh well....

User Image allcharts Posted - 11/30/22

$ARWR ARWR 2022-11-30 Dark Pool & Short Interest Data: https://www.youtube.com/watch?v=dBAKxsqEwo4

User Image diethylether Posted - 11/30/22

$ARWR some idiot just sold 5K at 31.

User Image burstingclownbubbles Posted - 11/30/22

$ARWR still no catalyst why should it go above the gap.

User Image tadmak Posted - 11/30/22

$ARWR

User Image MarketBeat Posted - 11/30/22

Arrowhead Pharmaceuticals's buy rating reiterated at The Goldman Sachs Group, Inc.. $66.00 PT. https://www.marketbeat.com/r/1858596 $ARWR

User Image Martin2029 Posted - 11/30/22

Big Gainer Alert: Trading today’s 9.4% move in ARROWHEAD PHARMACEUTICALS INC. $ARWR

User Image Chargedone Posted - 11/30/22

$ARWR upcoming data • Planning for the fazirsiran ARO-AAT P3 is complete and currently under review with the FDA, and SEQUOIA data are in. We expect to be able to give guidance on the P3 and present topline SEQUOIA data with Takeda shortly. • Interim P2 data from ARO-ANG3 and ARO-APOC3 suggest that both drug candidates are doing what they are designed to do, and we have good plans as to how to apply these in various patient populations. We expect multiple end-of-P2 meetings in 2023 and to initiate multiple Phase 3 studies shortly thereafter. • Progress with ARO-MUC5AC and ARO-RAGE in Phase 1/2 studies has been good. We expect interim data that could provide clinical proof of concept in the first half of 2023. • ARO-C3 is progressing well in a Phase 1/2 study and we expect interim data that could provide proof of concept in the first half of 2023. • Our discovery engine continues to perform and we expect to announce the next cell type we will be targeting in the first half of 2023

User Image William2026 Posted - 11/30/22

StockTwits Trending Alert: Trading recent interest in ARROWHEAD PHARMACEUTICALS INC. $ARWR

User Image burstingclownbubbles Posted - 11/30/22

$ARWR CEO needs to buy shares with his own capital. The day he does I buy another 5,000. Buy one share you clown.

User Image v1ko Posted - 11/30/22

$ARWR https://youtu.be/pF765zpIDGY

User Image Newsfilter Posted - 11/30/22

$ARWR B. Riley Securities analyst Mayank Mamtani maintains Arrowhead Pharmaceuticals with a Buy and lowers the price target from $65 to $59.

User Image Vpounder Posted - 11/30/22

$ARWR I feel like this is the true double bottom. Too much upside pressure with as long as the biotech bear market has lasted. M&A now front and center.

User Image burstingclownbubbles Posted - 11/30/22

$ARWR $30 stock and everyone thinks they're rich Fact only fraudzy is and his millions of freebies

Analyst Ratings
B. Riley Securities Buy Nov 30, 22
Jefferies Buy Nov 29, 22
Morgan Stanley Equal-Weight Nov 29, 22
SVB Leerink Market Perform Nov 29, 22
Piper Sandler Overweight Nov 10, 22
SVB Leerink Market Perform Nov 10, 22
Morgan Stanley Equal-Weight Sep 9, 22
Goldman Sachs Buy Aug 8, 22
HC Wainwright & Co. Buy Jun 3, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
San Martin Javier Chief Medical Office.. Chief Medical Officer Nov 21 Sell 30.3 19,500 590,850 91,500 11/22/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 27 Option 30.99 40,624 1,258,938 3,468,314 09/29/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jul 07 Option 14.54 2,501 36,365 4,060,135 07/11/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Feb 11 Option 5.19 146,388 759,754 4,204,022 02/14/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Feb 11 Sell 51.7 146,388 7,568,260 4,057,634 02/14/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 07 Option 5.19 11,806 61,273 4,057,634 01/07/22
O'Brien Patrick General Counsel General Counsel Jan 05 Sell 62.59 32,500 2,034,175 348,875 01/07/22
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 05 Sell 62.41 40,000 2,496,400 464,005 01/06/22
Hamilton James C Other Other Jan 04 Sell 64.84 25,625 1,661,525 155,625 01/06/22
GIVEN DOUGLAS B Director Director Dec 28 Buy 66.37 655 43,472 109,868 12/29/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 15 Sell 68.28 60,000 4,096,800 3,219,022 12/17/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Oct 20 Sell 65.96 65,000 4,287,400 3,279,022 10/22/21
O'Brien Patrick General Counsel General Counsel Feb 10 Option 5.22 90,000 469,800 383,375 02/10/21
O'Brien Patrick General Counsel General Counsel Feb 10 Sell 88.34 90,000 7,950,600 293,375 02/10/21
Hamilton James C Other Other Jan 15 Sell 81.4 10,000 814,000 126,250 01/15/21
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 12 Sell 81.01 13,038 1,056,208 444,005 01/12/21
O'Brien Patrick General Counsel General Counsel Jan 07 Sell 71.91 25,000 1,797,750 293,375 01/07/21
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 07 Sell 71.72 30,625 2,196,425 457,043 01/07/21
Hamilton James C Other Other Jan 07 Sell 72.25 38,750 2,799,688 136,250 01/07/21
PERRY MICHAEL S Director Director Jan 05 Sell 76.09 4,000 304,360 90,000 01/05/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 22 Option 5.45 40,510 220,780 2,545,747 12/22/20
GIVEN DOUGLAS B Director Director Dec 18 Sell 79.45 9,575 760,734 15,000 12/18/20
Waddill William D. Director Director Dec 11 Sell 70.8 3,000 212,400 25,000 12/11/20
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 10 Option 2.01 55,000 110,550 2,543,913 12/10/20
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 10 Sell 69.5 55,000 3,822,500 2,505,237 12/10/20
Bradshaw Curt Chief Scientific Off.. Chief Scientific Officer Nov 23 Sell 69.06 31,250 2,158,125 11/23/20
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Nov 12 Option 14.54 43,505 632,563 471,173 11/12/20
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Nov 12 Sell 69.45 43,505 3,021,422 427,668 11/12/20
De Backer Marianne Director Director Oct 26 Buy 50.47 1,000 50,470 17,500 10/26/20
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Oct 23 Sell 58.37 100,000 5,837,000 2,505,237 10/23/20
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Oct 22 Option 6.15 29,166 179,371 456,834 10/22/20
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Oct 22 Sell 54.04 29,166 1,576,131 427,668 10/22/20